t
Arecor Therapeutics plc issued and allotted 1,332 new Ordinary Shares of 1 pence each on 31 October 2023, following an exercise of options at an exercise price of 1 pence per share. Application has been made for these shares to be admitted to trading on AIM, with dealings expected to commence on or around 7 November 2023. Following admission, the total number of Ordinary Shares in issue will be 30,626,986.
| Date | 1 Nov 2023 |
| Time | 15:31:11 |
| Category | Capital structure |
| ID | 0901S |
Arecor Therapeutics plc
("Arecor" or the "Group")
Exercise of rollover options and Total Voting Rights
Cambridge, UK, 1 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that it has issued and allotted 1,332 new Ordinary Shares of 1 pence each in the share capital of the Company following an exercise of options on 31 October 2023 at an exercise price of 1 pence per Ordinary Share. The options exercised were part of the rollover of share options previously granted under the Arecor Limited EMI Share Option Plan 2018 ("Option Rollover"). Details of the Option Rollover are set out in the Company's Admission Document.
Admission
Following the above transactions, application has been made for the 1,332 new Ordinary Shares to be admitted to trading on AIM ("Admission") and dealings are expected to commence on, or around, 7 November 2023. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.
The total number of Ordinary Shares in issue following Admission will be 30,626,986. Accordingly, the figure of 30,626,986 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
|
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: [email protected] |
|
|
|
|
Mo Noonan, Communications |
Tel: +44 (0) 7876 444977 Email: [email protected] |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) |
|
|
Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
ICR Consilium |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: [email protected] |
|
|
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com